DGAP-Adhoc: Eckert & Ziegler to Purchase Isotope Company


ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Capital Increase/Acquisition

22.12.2008 

Release of a Adhoc News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Eckert & Ziegler to Purchase Isotope Company

Berlin, 22 December 2008 – Eckert & Ziegler Strahlen- und Medizintechnik AG
(ISIN DE 0005659700) today signed an agreement for the acquisition of a
business in the radioisotope industry with revenues in excess of 20 mm EUR.
The purchase price including cash (net working capital) is estimated to
around 6 mm EUR (and includes the assumption of liabilities). The Berlin
based specialist for radioactive applications is considering an increase in
capital in order to finance the transaction

Eckert & Ziegler is one of the largest manufacturers for radioactive
components for medical, industrial and scientific applications. It employs
about 420 staff members world wide and expects revenues of about 70 mm EUR
for 2008.

The Board of Directors.


Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax –112, E-mail: karolin.riehle@ezag.de,
www.ezag.de


DGAP 22.12.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
              Robert-Rössle-Str. 10
              13125 Berlin
              Deutschland
Phone:        +49 (0)30 941 084-0
Fax:          +49 (0)30 941 084-112
E-mail:       karolin.riehle@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700
WKN:          565970
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
              Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News                                     DGAP News-Service
---------------------------------------------------------------------------